Association between pancreatic cancer and diabetes: insights from a retrospective cohort study.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
11 Sep 2023
Historique:
received: 20 06 2023
accepted: 28 08 2023
medline: 13 9 2023
pubmed: 12 9 2023
entrez: 11 9 2023
Statut: epublish

Résumé

Studies investigating the prevalence of pancreatic cancer have revealed a heightened risk of 1.5 to 2.0 times among individuals with long-standing type 2 diabetes mellitus. We aimed to estimate the prevalence of diabetes among patients with pancreatic cancer, and identify the factors associated with type 2 diabetes mellitus in this population. This retrospective observational and analytical study was carried out in the Department of Gastroenterology of the Mohammed VI University Hospital over a period of 5 years, between 2018 and 2022, including all patients with confirmed cases of pancreatic adenocarcinoma. Out of the 197 patients, 38.1% had a history of diabetes, among them, 42.7% had new-onset diabetes, while the remaining 57.3% had long-standing diabetes. Diabetic patients were significantly older than nondiabetic patients (mean age of 67.2 vs. 63, P = 0.009). Diabetes was more prevalent among obese patients (66.7%, P = 0.01), and less frequent among individuals with chronic alcohol consumption (20% vs. 80%, P = 0.04), and tobacco smokers (24.4% vs75.6%, P = 0.03). Among patients with an ECOG score ≥ 3, DM, 54.5% were DM-patients (P = 0.033). The same significant association was found for the Nutritional Risk Index, Patients who had moderate or severe malnutrition were more likely to be diabetic 74.7% (P = 0.004). Diabetic patients were less likely to undergo surgery due to comorbidities and general health deterioration. However, no significant differences were observed in sex, tumor stage or location. Our study has shown an increased prevalence of diabetes in pancreatic cancer and highlights the importance of considering this cancer in cases of recent onset or uncontrolled diabetes, especially in elderly individuals.

Sections du résumé

BACKGROUND BACKGROUND
Studies investigating the prevalence of pancreatic cancer have revealed a heightened risk of 1.5 to 2.0 times among individuals with long-standing type 2 diabetes mellitus.
AIMS OBJECTIVE
We aimed to estimate the prevalence of diabetes among patients with pancreatic cancer, and identify the factors associated with type 2 diabetes mellitus in this population.
METHODS METHODS
This retrospective observational and analytical study was carried out in the Department of Gastroenterology of the Mohammed VI University Hospital over a period of 5 years, between 2018 and 2022, including all patients with confirmed cases of pancreatic adenocarcinoma.
RESULTS RESULTS
Out of the 197 patients, 38.1% had a history of diabetes, among them, 42.7% had new-onset diabetes, while the remaining 57.3% had long-standing diabetes. Diabetic patients were significantly older than nondiabetic patients (mean age of 67.2 vs. 63, P = 0.009). Diabetes was more prevalent among obese patients (66.7%, P = 0.01), and less frequent among individuals with chronic alcohol consumption (20% vs. 80%, P = 0.04), and tobacco smokers (24.4% vs75.6%, P = 0.03). Among patients with an ECOG score ≥ 3, DM, 54.5% were DM-patients (P = 0.033). The same significant association was found for the Nutritional Risk Index, Patients who had moderate or severe malnutrition were more likely to be diabetic 74.7% (P = 0.004). Diabetic patients were less likely to undergo surgery due to comorbidities and general health deterioration. However, no significant differences were observed in sex, tumor stage or location.
CONCLUSION CONCLUSIONS
Our study has shown an increased prevalence of diabetes in pancreatic cancer and highlights the importance of considering this cancer in cases of recent onset or uncontrolled diabetes, especially in elderly individuals.

Identifiants

pubmed: 37697301
doi: 10.1186/s12885-023-11344-w
pii: 10.1186/s12885-023-11344-w
pmc: PMC10496157
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

856

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

George S, et al. The role of type 2 diabetes in pancreatic Cancer. Cureus Jun. 2022. https://doi.org/10.7759/cureus.26288 .
doi: 10.7759/cureus.26288
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. Jun. 2014;74(11):2913–21. https://doi.org/10.1158/0008-5472.CAN-14-0155 .
Sun H, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. Jan. 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119 .
Duan X, Wang W, Pan Q, Guo L. Type 2 diabetes Mellitus intersects with pancreatic Cancer diagnosis and development. Front Oncol. Aug. 2021;11:730038. https://doi.org/10.3389/fonc.2021.730038 .
Lwanga SK, Lemeshow S, Lemeshow S. Détermination de la taille d’ un échantillon dans les études sanométriques: manuel pratique. Genève: Organisation Mondiale de la Santé; 1991.
Li Y, Bian X, Wei S, He M, Yang Y. “The relationship between pancreatic cancer and type 2 diabetes: cause and consequence,” Cancer Manag. Res, vol. Volume 11, pp. 8257–8268, Sep. 2019, https://doi.org/10.2147/CMAR.S211972 .
American Cancer Society. Cancer Facts & Fig. 2013. Atlanta: American Cancer Society; 2013.
Eibl G, et al. Diabetes Mellitus and obesity as risk factors for pancreatic Cancer. J Acad Nutr Diet. Apr. 2018;118(4):555–67. https://doi.org/10.1016/j.jand.2017.07.005 .
Andersen DK, et al. Diabetes. ” Diabetes. May 2017;66(5):1103–10. https://doi.org/10.2337/db16-1477 . Pancreatogenic Diabetes, and Pancreatic Cancer.
Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. “Prevalence and Clinical Profile of Pancreatic Cancer–Associated Diabetes Mellitus,” Gastroenterology, vol. 134, no. 4, pp. 981–987, Apr. 2008, https://doi.org/10.1053/j.gastro.2008.01.039 .
Korc M. Pathogenesis of pancreatic Cancer-related diabetes Mellitus: Quo Vadis? Pancreas. May 2019;48(5):594–7. https://doi.org/10.1097/MPA.0000000000001300 .
Lee HS, et al. Difference of risk of pancreatic Cancer in New-Onset Diabetes and Long-standing diabetes: a Population-based Cohort Study. J Clin Endocrinol Metab. May 2023;108(6):1338–47. https://doi.org/10.1210/clinem/dgac728 .
Zendehdel K. “Cancer Incidence in Patients With Type 1 Diabetes Mellitus: A Population-Based Cohort Study in Sweden,” CancerSpectrum Knowl. Environ, vol. 95, no. 23, pp. 1797–1800, Dec. 2003, https://doi.org/10.1093/jnci/djg105 .
Lv X, Qiao W, Leng Y, Wu L, Zhou Y. Impact of diabetes mellitus on clinical outcomes of pancreatic cancer after surgical resection: a systematic review and meta-analysis. PLoS ONE. Feb. 2017;12(2):e0171370. https://doi.org/10.1371/journal.pone.0171370 .
Toriola AT, Stolzenberg-Solomon R, Dalidowitz L, Linehan D, Colditz G. Diabetes and pancreatic cancer survival: a prospective cohort-based study. Br J Cancer. Jul. 2014;111(1):181–5. https://doi.org/10.1038/bjc.2014.224 .
Hwang A, Narayan V, Yang Y-X. “Type 2 diabetes mellitus and survival in pancreatic adenocarcinoma: A retrospective cohort study,” Cancer, vol. 119, no. 2, pp. 404–410, Jan. 2013, https://doi.org/10.1002/cncr.27731 .
Li D, Mao Y, Chang P, Liu C, Hassan MM, Yeung SJ, Abbruzzese JL. Impacts of new-onset and long-term diabetes on clinical outcome of pancreatic cancer. Am J Cancer Res. 2015;5(10):3260–9. PMID: 26693076; PMCID: PMC4656747.
pubmed: 26693076 pmcid: 4656747

Auteurs

Fakhrddine Amri (F)

Department of Hepato-Gastroenterology, Mohammed VI University Hospital, Oujda University, Oujda, BP 4806, 60049, Morocco. fakh.amr@gmail.com.
Digestive Diseases Research Laboratory (DSRL), Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco. fakh.amr@gmail.com.

Chifaa Belkhayat (C)

Department of Hepato-Gastroenterology, Mohammed VI University Hospital, Oujda University, Oujda, BP 4806, 60049, Morocco.
Digestive Diseases Research Laboratory (DSRL), Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco.

Asmae Yeznasni (A)

Laboratory of Epidemiology, Clinical Research, and Public Health, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco.

Hajar Koulali (H)

Department of Hepato-Gastroenterology, Mohammed VI University Hospital, Oujda University, Oujda, BP 4806, 60049, Morocco.
Digestive Diseases Research Laboratory (DSRL), Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco.

Rachid Jabi (R)

Department of General Surgery, Mohammed VI University Hospital, Oujda, Morocco.

Abdelkrim Zazour (A)

Department of Hepato-Gastroenterology, Mohammed VI University Hospital, Oujda University, Oujda, BP 4806, 60049, Morocco.
Digestive Diseases Research Laboratory (DSRL), Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco.

Naima Abda (N)

Laboratory of Epidemiology, Clinical Research, and Public Health, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco.

Mohammed Bouziane (M)

Department of General Surgery, Mohammed VI University Hospital, Oujda, Morocco.

Zahi Ismaili (Z)

Department of Hepato-Gastroenterology, Mohammed VI University Hospital, Oujda University, Oujda, BP 4806, 60049, Morocco.
Digestive Diseases Research Laboratory (DSRL), Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco.

Ghizlane Kharrasse (G)

Department of Hepato-Gastroenterology, Mohammed VI University Hospital, Oujda University, Oujda, BP 4806, 60049, Morocco.
Digestive Diseases Research Laboratory (DSRL), Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH